FDA Slaps Sun Pharma's India Plant with Warning Letter

Jan 05, 2016

In late December, India-based Sun Pharma received a warning letter citing sterility concerns at its manufacturing site in Halol, India. In the letter, inspectors reported there were buckets in the parenteral manufacturing space collecting water from overhead leaks. FDA concerns included the way that media fill records failed to include a specific description for why Sun rejected vials from certain batches.

Also, the company failed to perform adequate airflow studies to determine how the movement of air and personnel during aseptic operations could pose sterility risks.

To learn more, read the FDA warning letter

View the most popular news stories in 2015 from Pharmaceutical Manufacturing.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments